NRx Pharma partner Emobot's EMOCARE shows 90% concordance with MADRS
NRx Pharmaceuticals announced that its strategic partner, Emobot Health, presented the first pooled clinical validation of EMOCARE, a smartphone-based "Depression Thermometer," at the 2026 Annual Meeting of the American Society of Clinical Psychopharmacology. Pooled analysis of three prospective observational studies demonstrated 90% within-person concordance between EMOCARE scores and clinician-rated MADRS (r = 0.895; p = 0.016). The tool also showed strong sensitivity to symptom change against PHQ-9 (ρ = 0.834; p < 0.001). This validated technology is now being deployed across the Hope Therapeutics interventional psychiatry network, a subsidiary of NRx, to provide continuous, real-time monitoring of depressive symptoms.
Key Highlights
- Emobot Health presented pooled clinical validation of EMOCARE at the 2026 ASCP Annual Meeting.
- EMOCARE is a smartphone-based passive monitoring tool for depression, using voice, facial expression, motion, and screen behavior.
- Pooled analysis showed 90% within-person concordance with clinician-rated MADRS (r = 0.895; p = 0.016).
- Achieved strong sensitivity to symptom change against PHQ-9 (ρ = 0.834; p < 0.001) on consecutive-visit measurements.
- The validated EMOCARE technology is being deployed across the Hope Therapeutics interventional psychiatry network.
- NRx Pharmaceuticals CEO Jonathan C. Javitt co-authored the poster and highlighted EMOCARE's value.
- EMOCARE aims to provide continuous, real-time patient monitoring between episodic clinician visits.
Price Impact
More from NRXP